EA201891170A1 - Биомаркер поликистозной болезни почек и варианты его применения - Google Patents
Биомаркер поликистозной болезни почек и варианты его примененияInfo
- Publication number
- EA201891170A1 EA201891170A1 EA201891170A EA201891170A EA201891170A1 EA 201891170 A1 EA201891170 A1 EA 201891170A1 EA 201891170 A EA201891170 A EA 201891170A EA 201891170 A EA201891170 A EA 201891170A EA 201891170 A1 EA201891170 A1 EA 201891170A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pkd
- patient
- kidney disease
- polycystic kidney
- biomarker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257089P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062075 WO2017087409A1 (en) | 2015-11-18 | 2016-11-15 | Biomarker of polycystic kidney disease and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201891170A1 true EA201891170A1 (ru) | 2018-11-30 |
Family
ID=57539614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891170A EA201891170A1 (ru) | 2015-11-18 | 2016-11-15 | Биомаркер поликистозной болезни почек и варианты его применения |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11116755B2 (https=) |
| EP (1) | EP3377908B1 (https=) |
| JP (1) | JP6895963B2 (https=) |
| KR (1) | KR20180083902A (https=) |
| CN (1) | CN108700594B (https=) |
| AU (1) | AU2016357720A1 (https=) |
| BR (1) | BR112018009879A2 (https=) |
| CO (1) | CO2018006126A2 (https=) |
| EA (1) | EA201891170A1 (https=) |
| MX (1) | MX2018006250A (https=) |
| WO (1) | WO2017087409A1 (https=) |
| ZA (1) | ZA201803035B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201891170A1 (ru) | 2015-11-18 | 2018-11-30 | Джензим Корпорейшн | Биомаркер поликистозной болезни почек и варианты его применения |
| CN114040762A (zh) * | 2019-02-04 | 2022-02-11 | 建新公司 | 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病 |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
| JPWO2023145898A1 (https=) * | 2022-01-27 | 2023-08-03 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710227B1 (en) | 1998-09-16 | 2004-03-23 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
| US6703395B2 (en) | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| CA2256121A1 (en) | 1998-06-08 | 1999-12-08 | Hong Wang | Cyclin-dependent kinase inhibitors as plant growth regulators |
| WO1999065910A1 (en) | 1998-06-16 | 1999-12-23 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fused azepinone cyclin dependent kinase inhibitors |
| US6559152B2 (en) | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| KR100708573B1 (ko) | 1999-05-24 | 2007-04-18 | 에이브이아이 바이오파마 인코포레이티드 | 다낭 신장 질환의 치료를 위한 ｃ-ｍｙｃ에 대한 안티센스 |
| US6593356B2 (en) | 1999-10-20 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| EP1278749B1 (en) | 2000-04-25 | 2005-01-26 | Bristol-Myers Squibb Company | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| WO2002022133A1 (en) | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| EP1345941A1 (fr) | 2000-12-20 | 2003-09-24 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| AU2002365211A1 (en) | 2001-07-10 | 2003-09-02 | Bristol-Myers Squibb Pharma Company | 6-substituted pyrazolo (3,4-d) pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| MY137843A (en) | 2002-09-04 | 2009-03-31 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| NZ539163A (en) | 2002-09-04 | 2007-03-30 | Schering Corp | Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CA2497444C (en) | 2002-09-04 | 2010-11-30 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| KR20050057139A (ko) | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| ATE378336T1 (de) | 2002-09-19 | 2007-11-15 | Schering Corp | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| AR041292A1 (es) | 2002-09-19 | 2005-05-11 | Schering Corp | Pirazolopiridinas como inhibidores de quinasa dependientes de ciclina |
| US7576085B2 (en) | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| US7186740B2 (en) | 2002-09-23 | 2007-03-06 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| TW200413378A (en) | 2002-09-23 | 2004-08-01 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| US9006181B2 (en) | 2004-07-21 | 2015-04-14 | The Administrators Of The Tulane Educational Fund | Treatment of renal dysfunction and multiple myeloma using PACAP compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| JP5661457B2 (ja) * | 2007-06-06 | 2015-01-28 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． | 腎疾患の予測診断 |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP3078373A1 (en) | 2008-10-03 | 2016-10-12 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitor |
| US20120077263A1 (en) | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| CN102018702B (zh) | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| WO2011066352A1 (en) | 2009-11-27 | 2011-06-03 | Genzyme Corporation | An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase |
| WO2011084548A2 (en) * | 2009-12-15 | 2011-07-14 | King Faisal Specialist Hospital & Research Centre | Methods and compositions for detecting recesssive familial fsgs and uses thereof |
| ES2606140T3 (es) | 2010-10-01 | 2017-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| JP6021021B2 (ja) * | 2010-11-05 | 2016-11-02 | 国立大学法人京都大学 | 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 |
| KR20140072160A (ko) * | 2011-10-03 | 2014-06-12 | 셀매틱스, 인크. | 추정 자손에 대한 상태 발병 위험을 평가하는 방법 및 장치 |
| WO2013059119A1 (en) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| CN102590491B (zh) | 2012-02-06 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途 |
| US10478446B2 (en) | 2012-07-03 | 2019-11-19 | Fondazione Centro San Raffaele Office Of Biotechnology Transfer | Compounds for use in polycystic kidney disease |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2016022500A2 (en) | 2014-08-04 | 2016-02-11 | Genzyme Corporation | Biomarkers of polycystic kidney disease and uses thereof |
| EA201891170A1 (ru) | 2015-11-18 | 2018-11-30 | Джензим Корпорейшн | Биомаркер поликистозной болезни почек и варианты его применения |
-
2016
- 2016-11-15 EA EA201891170A patent/EA201891170A1/ru unknown
- 2016-11-15 MX MX2018006250A patent/MX2018006250A/es unknown
- 2016-11-15 KR KR1020187016766A patent/KR20180083902A/ko not_active Withdrawn
- 2016-11-15 EP EP16809582.6A patent/EP3377908B1/en active Active
- 2016-11-15 WO PCT/US2016/062075 patent/WO2017087409A1/en not_active Ceased
- 2016-11-15 BR BR112018009879A patent/BR112018009879A2/pt not_active Application Discontinuation
- 2016-11-15 US US15/775,736 patent/US11116755B2/en active Active
- 2016-11-15 AU AU2016357720A patent/AU2016357720A1/en not_active Abandoned
- 2016-11-15 CN CN201680079045.XA patent/CN108700594B/zh active Active
- 2016-11-15 JP JP2018525768A patent/JP6895963B2/ja active Active
-
2018
- 2018-05-09 ZA ZA2018/03035A patent/ZA201803035B/en unknown
- 2018-06-15 CO CONC2018/0006126A patent/CO2018006126A2/es unknown
-
2021
- 2021-08-17 US US17/404,701 patent/US12150938B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12150938B2 (en) | 2024-11-26 |
| CN108700594B (zh) | 2021-06-29 |
| JP2019502902A (ja) | 2019-01-31 |
| AU2016357720A1 (en) | 2018-07-05 |
| EP3377908B1 (en) | 2020-08-05 |
| CO2018006126A2 (es) | 2018-07-10 |
| BR112018009879A2 (pt) | 2018-11-13 |
| KR20180083902A (ko) | 2018-07-23 |
| US20180338961A1 (en) | 2018-11-29 |
| US11116755B2 (en) | 2021-09-14 |
| US20210379031A1 (en) | 2021-12-09 |
| EP3377908A1 (en) | 2018-09-26 |
| JP6895963B2 (ja) | 2021-06-30 |
| MX2018006250A (es) | 2018-09-05 |
| WO2017087409A1 (en) | 2017-05-26 |
| CN108700594A (zh) | 2018-10-23 |
| ZA201803035B (en) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
| EA201500835A1 (ru) | Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты | |
| MX387936B (es) | Metodo para la cuantificacion de huevos de parasitos en las heces. | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| WO2015176066A3 (en) | Lpa-associated protein and rna expression | |
| JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
| EP4417218A3 (en) | Methods for determining dpp3 and therapeutic methods | |
| EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
| BR112016002845A2 (pt) | composições e métodos para tratar condições associadas ao complemento | |
| EP3606507A4 (en) | SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER | |
| DK2885641T3 (da) | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension | |
| BR112016018205A2 (pt) | métodos de tratamento de mal de alzheimer | |
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| MX380238B (es) | Anticuerpos especificos para mmp9. | |
| BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
| EA201990730A1 (ru) | Рнк-биомаркеры для наследственного ангионевротического отека | |
| BR112018008799A2 (pt) | método de prognóstico | |
| EP3779456A4 (en) | QUANTIFICATION METHOD, QUANTIFICATION REAGENT AND QUANTIFICATION KIT FOR LIPOPROTEIC CHOLESTEROL | |
| EA201891170A1 (ru) | Биомаркер поликистозной болезни почек и варианты его применения | |
| MX374415B (es) | Composiciones y métodos para identificar un riesgo de cáncer en un sujeto. | |
| SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
| EA201890739A1 (ru) | Анти-s100a8 для лечения лейкемии | |
| EA201792669A1 (ru) | Igfbp3 и его применение | |
| BR112019007426A2 (pt) | método para reduzir a proteinúria em um sujeito humano que sofre de igan. | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. |